USFDA Concludes Inspection of Aurobindo Pharma Subsidiary with 2 Observations
Written By : Parthika Patel
Published On 2026-06-30 12:24 GMT | Update On 2026-06-30 12:24 GMT
Advertisement
New Delhi: Aurobindo Pharma Limited has informed the stock exchanges that the United States Food and Drug Administration (USFDA) has completed an inspection at Auroactive Pharma Private Limited, its wholly owned subsidiary, with the inspection concluding with two observations.
The company disclosed the development under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, stating that the inspection was conducted at the subsidiary's manufacturing facility located at Sy Nos. 231, 285 to 291, Sancham Village, Ranasthalam Mandal, Srikakulam District, Andhra Pradesh – 523409, from June 22, 2026, to June 26, 2026.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.